Hot Features
Premium
Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Period:
Draw Mode:
| Volume | 0 |
|
|||||
| News | - | ||||||
| Day High | Low High |
||||||
| Day Low | |||||||
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Forte Biosciences Inc | FBRX | NASDAQ | Common Stock |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 0.725 | 07:09:16 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 0.725 |
| Trades | Shares Traded | Average Volume | 52 Week Range |
|---|---|---|---|
| 0 | 0 | - | 0.38 - 1.1497 |
| Last Trade | Type | Quantity | Price | Currency |
|---|---|---|---|---|
| - | 0 | US$ 0.725 | USD |
Forte Biosciences Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 45.78M | 36.34M | - | 0 | -31.48M | -0.87 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Forte Biosciences News
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical FBRX Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 0.7209 | 0.767 | 0.71 | 0.7245273 | 8,241 | 0.0041 | 0.57% |
| 1 Month | 0.7139 | 0.78 | 0.62 | 0.7249527 | 24,659 | 0.0111 | 1.55% |
| 3 Months | 0.4691 | 0.78 | 0.445 | 0.6898802 | 33,281 | 0.2559 | 54.55% |
| 6 Months | 0.491 | 0.85 | 0.38 | 0.6355491 | 37,211 | 0.234 | 47.66% |
| 1 Year | 1.07 | 1.1497 | 0.38 | 0.8129512 | 47,224 | -0.345 | -32.24% |
| 3 Years | 36.08 | 43.57 | 0.38 | 6.48 | 309,216 | -35.36 | -97.99% |
| 5 Years | 17.00 | 53.99 | 0.38 | 8.95 | 264,727 | -16.28 | -95.74% |
Forte Biosciences Description
| Forte Biosciences Inc is a clinical-stage biopharmaceutical company, focused on dermatology. The company is developing a live biotherapeutic, FB-401, for the treatment of inflammatory skin diseases. FB-401 has completed Phase 1/2a testing in adult and pediatric patients with atopic dermatitis. It plans to advance FB-401 into a randomized Phase 2 clinical trial. |
